Impax Asset Management Group plc Buys 815,403 Shares of Boston Scientific Co. (NYSE:BSX)

Impax Asset Management Group plc increased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 17.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,470,174 shares of the medical equipment provider's stock after purchasing an additional 815,403 shares during the quarter. Boston Scientific accounts for about 1.8% of Impax Asset Management Group plc's investment portfolio, making the stock its 12th largest holding. Impax Asset Management Group plc owned approximately 0.37% of Boston Scientific worth $457,138,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BSX. Quintet Private Bank Europe S.A. raised its holdings in shares of Boston Scientific by 26.3% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 23,581 shares of the medical equipment provider's stock valued at $1,976,000 after buying an additional 4,914 shares during the period. World Equity Group Inc. purchased a new stake in shares of Boston Scientific during the third quarter valued at approximately $270,000. PDS Planning Inc lifted its position in shares of Boston Scientific by 2.7% during the third quarter. PDS Planning Inc now owns 7,361 shares of the medical equipment provider's stock worth $617,000 after purchasing an additional 192 shares in the last quarter. TKG Advisors LLC acquired a new stake in Boston Scientific during the 3rd quarter valued at $2,180,000. Finally, QRG Capital Management Inc. increased its stake in Boston Scientific by 21.6% during the 3rd quarter. QRG Capital Management Inc. now owns 104,462 shares of the medical equipment provider's stock worth $8,754,000 after buying an additional 18,573 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the sale, the executive vice president now directly owns 160,467 shares of the company's stock, valued at $13,639,695. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares in the company, valued at $3,061,135.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of Boston Scientific stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the sale, the executive vice president now directly owns 160,467 shares of the company's stock, valued at $13,639,695. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 309,270 shares of company stock worth $26,196,718. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of BSX traded up $1.10 during mid-day trading on Monday, hitting $84.72. The company's stock had a trading volume of 5,811,692 shares, compared to its average volume of 6,104,429. Boston Scientific Co. has a fifty-two week low of $50.84 and a fifty-two week high of $88.79. The stock has a market capitalization of $124.76 billion, a price-to-earnings ratio of 69.11, a PEG ratio of 2.47 and a beta of 0.79. The firm has a 50-day moving average price of $84.00 and a 200 day moving average price of $78.43. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.41% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the company posted $0.50 EPS. The company's revenue was up 19.3% compared to the same quarter last year. On average, research analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BSX. Mizuho lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. BTIG Research raised their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Canaccord Genuity Group boosted their target price on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Sanford C. Bernstein upped their price target on Boston Scientific from $92.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. Finally, Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $87.00 to $98.00 and gave the stock an "overweight" rating in a report on Thursday, October 24th. Three research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.